GRAIL reports Q3 2026 results as FDA panel backs Galleri approval
An FDA advisory panel voted in favor of the Galleri multi-cancer test in September, with GRAIL saying it expects a decision by early Q1 2027.
SEC filing
Latest
1 story
Sign inSign in1 story
An FDA advisory panel voted in favor of the Galleri multi-cancer test in September, with GRAIL saying it expects a decision by early Q1 2027.
SEC filing